Sandoz expands biosimilar access, world-first cancer research centre launches in NSW, alarming rise in GHB deaths, and more
Click here to download Pharmacy Daily for Tuesday 3rd February 2026
PARTNER SITES
Other recent headlines
-
Sandoz expands biosimilar access
Tuesday | Feb 3 2026SANDOZ has announced the listing of the first aflibercept biosimilar, AFQLIR, on the Pharmaceutical Benefits Scheme (PBS), improving access to ophthalmology treatments for Australians living with multiple neovascular-related conditions.
-
World-first cancer research centre
Tuesday | Feb 3 2026THE Cancer Council NSW and the University of NSW (UNSW) have entered into a $40 million, 10-year partnership to launch a cancer survivorship centre this Thu.
-
GHB taking a bigger toll
Tuesday | Feb 3 2026GHB-RELATED deaths have increased 10-fold since 2013, while the number of hospitalisations more than tripled, according to an Australian-first study from the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney.
to top